Supplementary Tables:

Table S1: Baseline characteristics of patients who received heart transplant for light chain (AL) or transthyretin (ATTR) cardiac amyloidosis, separated by era. Early Era, 2001-1007; Late Era 2008-2018.

	AL			ATTR		
	Early Era	Late Era	p-value	Early Era	Late Era	p-value
Demographics	(n = 12)	(n = 6)		(n =6)	(n =15)	
Female, n (%)	6 (50.0)	1 (16.7)	0.32	2 (33.3)	2 (33.3)	0.54
Age at OHT, years	52 (47.8-56.3)	59 (55.3-62.0)	0.38	60.5 (53.5-63.8)	63 (58.5-66.0)	0.50
Diagnosis to OHT, days	116 (74.8-148.5)	643 (375-1231)	0.03	162 (698.8-340.5)	389 (245.5-861.5)	0.08
Listing to OHT, days	33 (22-107)	66 (58-331)	0.55	48.5 (40.8-76.3)	70.5 (37.0-149.0)	0.78
Laboratory						
BMI, kg/ m^2	26.1 (24.4-28.6)	25.4 (24.8-26.2)	0.88	25.4 (24.8-26.2)	27 (24.6-28.9)	0.11
mBMI, kg/m^2	939 (835-1080)	1170 (1090-1230)	0.06	1170 (1090-1230)	1110 (997-1250)	0.08
Creatinine, mg/dL	1.1 (1.0-1.5)	1.3 (1.1-1.7)	0.93	1.5 (0.9-2.1)	1.3 (1.1-1.5)	0.76
eGFR, ml/min/1.73 m^2	54.3 (45.1-66.7)	59.7 (46.8-71.7)	0.24	47.6 (35.7-77.8)	60.6 (47.1-71.8)	0.38
Serum albumin, g/L	3.7 (3.3-4.0)	4.6 (4.3-4.7)	0.01	4.2 (4.0-4.3)	4.2 (4.1-4.4)	0.93

Total Bilirubin, mg/dL	0.9 (0.5-1.1)	0.8 (0.7-0.9)	0.76	0.8 (0.7-0.9)	0.9 (0.7-1.2)	0.18
Alkaline Phosphatase, U/L	104 (92-114)	88.5 (77.5-102.0)	0.17	104 (80.5-125.0)	80 (68.5-122)	0.51
Clinical Data						
Average NYHA class	3.6 ± 0.5	3.5 ± 0.6	0.79	3.8 ± 0.4	3.7 ± 0.5	0.67
Hypertension, n (%)	4 (33)	2 (33.3)	1.00	3 (50)	6 (40)	1.00
Diabetes, n (%)	3 (25)	1 (16.7)	1.00	2 (33.3)	1 (6.7)	0.18
CAD, n (%)	3 (25)	3 (50)	0.34	1 (16.7)	5 (33.3)	0.62
Peripheral neuropathy, n (%)	0 (0)	1 (16.7)	0.33	2 (33.3)	4 (26.7)	1.00
Organs affected			1.00			0.18
Isolated cardiac, n (%)	9 (75)	5 (83.33)		4 (66.7)	14 (93.3)	
2 organs affected, n (%)	3(25)	1 (16.67)		2 (33.3)	1 (6.7)	

AL= light chain amyloidosis; ATTR = transthyretin amyloidosis; mBMI = modified body mass index; CAD = coronary artery disease; eGFR, by MDRD equation = estimated glomerular filtration rate; mBMI = modified body mass index; MDRD = modification of diet in renal disease; NYHA = New York Heart Association Class; OHT = orthotopic heart transplantation.

Values are given as median (25th-75th percentile), mean ± standard deviation, or counts (%)

Table S2: Treatment Regimens and Management of Light-Chain Cardiac Amyloidosis

Patients

AL Subject #	Era	SCT	Chemotherapy Regimen	Induction[a]	Consolidation[b]
1	Early	Y	M, 140 mg/m^2	n/a	n/a
2	Early	Y	M, 140 mg/m^2	n/a	n/a
3	Early	Y	M, 140 mg/m^2	n/a	n/a
4	Early	Y	M, 140 mg/m^2	n/a	n/a
5	Early	N	Fludarabine	n/a	n/a
6	Early	Y	M, 140 mg/m^2	n/a	Len, Cy, Dexa
7[c]	Early	Y	M, 140 mg/m^2	n/a	n/a
8	Early	Y	M, 140 mg/m^2	n/a	n/a
9	Early	Y	M, 140 mg/m^2	n/a	n/a
10	Early	Y	M, 140 mg/m^2	n/a	n/a
11	Early	Y	M, 200 mg/m^2	n/a	n/a
12	Early	Y	M, 200 mg/m^2	n/a	n/a
13	Late	N	Len, Dexa, Bor, oral M	n/a	n/a
14	Late	Y	M, 140 mg/m^2	n/a	CyBorD, Dara
15	Late	Y	M, 140 mg/m^2	n/a	Thal, Dexa, Bor
16[c]	Late	Y	M, 140 mg/m^2	n/a	Bor, Dexa
17	Late	Y	M, 140 mg/m^2	n/a	Bor, Dexa
18[c]	Late	Y	M, 140 mg/m^2	CyBorD[d]	Ixazomib, Dara, Dexa

AL = light chain amyloidosis; SCT = stem cell transplant; Bor = bortezomib; Cy = cyclophosphamide; CyBorD = Cyclophosphamide, bortezomib, dexamethasone; Dara = daratumumab; Dexa = dexamethasone; Len = lenalidomide; M = melphalan.

[a] Induction: defined as initial pre-stem cell transplant chemotherapy regimen

[b] Consolidation: defined as initial post-stem cell chemotherapy regimen

[c] Received SCT before heart transplant